ABVX — Abivax S.A.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1956827 ·
France
Last close
$102.72
Market Cap
$8.19B
52W High
$135.07
52W Low
$69.81
ADV30
2,193,284
Next earnings
2026-03-23
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -56,229,000 | -48,468,000 | 547,142,000 | 477,423,000 | 117,548,000 |
| Dec 2025 | 0 | — | -71,648,000 | -81,960,000 | 584,341,000 | 516,685,000 | 129,136,000 |
| Sep 2025 | 0 | — | -80,712,000 | -153,358,000 | 652,052,000 | 589,703,000 | 140,814,000 |
| Jun 2025 | 0 | — | -46,496,000 | -48,414,000 | 119,641,000 | 60,946,000 | 167,921,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-161,130,000
Investing CF
$-8,193,000
Financing CF
$547,307,000
CapEx
$-243,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-4.56
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-738,482,000
Inventory
—
Receivables
$10,495,000
ST Investments
$13,698,000
EBIT TTM
$-302,711,000
Pretax Income TTM
$-330,254,000
Interest Exp TTM
$27,543,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,920,000
EBITDA
$-254,004,000
Free Cash Flow
$-114,471,872
Enterprise Value
$7,593,093,120
Total Cash
$491,552,000
Total Debt
$34,211,000
Shares Out
79,694,535
Trailing EPS
$-5.31
Book Value
$6.30
ROE
-157.1%
ROA
-44.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -246,056,000 | -336,102,000 | 584,341,000 | 129,136,000 | — | -161,129,000 |
| Dec 2024 | 0 | -172,984,000 | -176,242,000 | 205,228,000 | 164,644,000 | — | -154,072,000 |
| Dec 2023 | 0 | -127,377,000 | -147,740,000 | 327,062,000 | 131,052,000 | — | -97,130,000 |
| Dec 2022 | 0 | -51,205,000 | -60,740,000 | 75,544,000 | 68,355,000 | — | -53,936,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.89
Max Pain — expiry 2026-06-12 (volume-derived — Yahoo OI feed degraded)
max pain strike: $101.00 · spot: $102.72 · call volume: 1,105 · put volume: 1,009
Expected Move to 2026-06-12:
±$10.48
(10.20%) —
implied range
$92.24 –
$113.20
· ATM straddle on $103.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AAVXF | Abivax S.A. | $8.07B | $101.25 | — |
| CORT | CORCEPT THERAPEUTICS INC | $8.32B | $77.49 | — |
| NUVL | Nuvalent, Inc. | $9.07B | $123.25 | — |
| ALKS | Alkermes plc. | $7.38B | $44.29 | — |
| CYTK | CYTOKINETICS INC | $9.29B | $68.45 | — |
News headlines (Yahoo Finance, 1h cache)
European Value Stocks Trading Below Estimated Intrinsic Values June 2026
2026-06-10 05:38 · Yahoo
High Growth Tech Stocks To Watch In The Global Market
2026-06-05 09:42 · Yahoo
Abivax (ABVX) Jumps 16% on Bargain-Hunting
2026-06-05 01:30 · Yahoo
Abivax (ABVX) Skyrockets 24% After Steep Fall
2026-06-04 02:54 · Yahoo
This Stock Is Up 1,000% Over the Past Year. Is There More Upside Ahead?
2026-06-03 21:35 · Yahoo
Assessing Abivax (ENXTPA:ABVX) Valuation After Phase 3 Obefazimod Data And Safety Concerns
2026-06-03 21:17 · Yahoo
Abivax SA Sponsored ADR (ABVX) Loses 41.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-06-03 13:35 · Yahoo
ABVX Stock Clocks Worst Day Ever On Malignancy Signal For Drug: ‘Pharma Bro’ Says ‘GLPs Are Doing Fine’ After Similar Fears
2026-06-03 00:01 · Yahoo
Abivax Hits 'Best-Case' Scenario For Ulcerative Colitis Drug; So, Why Did Shares Plummet?
2026-06-02 20:29 · Yahoo
Sector Update: Healthcare Stocks Softer Late Afternoon
2026-06-02 19:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.